Selective Resection of Type 1 Gastric Neuroendocrine Neoplasms and the Risk of Progression in an Endoscopic Surveillance Programme
Digestive Surgery · 2021 · 38 (1) · 38-45
DOI: 10.1159/000510962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Surgery, online erschienen am 01.12.2020. Verfasst von Jun Liong Chin und 9 weiteren Autor:innen. Beteiligte Einrichtung: ENETS Neuroendocrine Tumour Centre of Excellence, St. Vincent's University Hospital, University College, Dublin, Ireland, junliong@hotmail.com. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Current guidance for type 1 gastric neuroendocrine neoplasms (gNENs) recommends either resection of all visible lesions or selective resection of gNENs >10 mm. We adopt a selective strategy targeting lesions approaching 10 mm for endoscopic mucosal resection (EMR) and provide surveillance for smaller lesions.
Objectives
This study aimed to describe the incidence of type 1 gNENs requiring endoscopic/surgical resection and the risk of disease progression (both considered significant disease) on endoscopic surveillance. The secondary objective was to assess the risk factors for disease progression during surveillance and the incidence of gastric dysplasia/adenoma/adenocarcinoma.
Methods
We collected consecutive patients with type 1 gNENs and obtained demographic and clinical data through the electronic patient record.
Results
In our cohort of 57 patients, 12 patients had EMR at index gastroscopy; 7 patients had surgery (4: large/multiple gNENs and 3: nodal metastases) (5.2% [3/57] risk of nodal metastases); and a patient with nodal and liver metastases (1.8% [1/57] risk of distant metastases). The prevalence of gastric adenocarcinoma in our study was 3.5% with an incidence rate of 9.59 per 1,000 persons per year. For patients undergoing surveillance, 29.5% (13/44) of patients progressed requiring resection. Serum gastrin was significantly higher in patients who progressed to resection (p value = 0.023).
Conclusion
We concluded that up to a third of patients with type 1 gNENs have significant disease requiring resection. Hence, endoscopic surveillance and resect strategy would benefit patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ENETS Neuroendocrine Tumour Centre of Excellence, St. Vincent's University Hospital, University College, Dublin, Ireland, junliong@hotmail.com.
- St. James's Hospital, Trinity College, Dublin, Ireland, junliong@hotmail.com.
- St. James's Hospital, Trinity College, Dublin, Ireland.
- ENETS Neuroendocrine Tumour Centre of Excellence, St. Vincent's University Hospital, University College, Dublin, Ireland.
- Tallaght Hospital, Trinity College, Dublin, Ireland.
Zitieren
APA
Chin, J. L., O'Connell, J., Muldoon, C., Swan, N., Reynolds, J. V., Ravi, N., Geoghegan, J., Conlon, K. C., O'Shea, D., & O'Toole, D. (2021). Selective Resection of Type 1 Gastric Neuroendocrine Neoplasms and the Risk of Progression in an Endoscopic Surveillance Programme. Digestive Surgery, 38(1), 38-45. https://doi.org/10.1159/000510962
Vancouver
Chin JL, O'Connell J, Muldoon C, Swan N, Reynolds JV, Ravi N, et al. Selective Resection of Type 1 Gastric Neuroendocrine Neoplasms and the Risk of Progression in an Endoscopic Surveillance Programme. Digestive Surgery. 2021;38(1):38-45. doi:10.1159/000510962
BibTeX
@article{Chin2021,
author = {Chin, Jun Liong and O'Connell, Jim and Muldoon, Cian and Swan, Niall and Reynolds, John Vincent and Ravi, Narayanasamy and Geoghegan, Justin and Conlon, Kevin C and O'Shea, Donal and O'Toole, Dermot},
title = {Selective Resection of Type 1 Gastric Neuroendocrine Neoplasms and the Risk of Progression in an Endoscopic Surveillance Programme},
journal = {Digestive Surgery},
year = {2021},
volume = {38},
number = {1},
pages = {38--45},
doi = {10.1159/000510962}
}
EUVIMED